Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Multivitamins are the most common dietary supplement in the U.S. People take these pills (or gummies, indeed) for a variety of health reasons, but the science on what multivitamins may do for your ...

A capsule sponge test takes ten minutes to do and can be done by a nurse – said to make it much faster and less expensive than an endoscopy. The trial will find out if the capsule sponge test can ...

Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.

Scientists at Brigham and Women’s Hospital and others studied thousands of older adults who were asked to take a daily multivitamin and multimineral supplement. They found evidence that daily ...